CA2364253A1 - Dihydroxy open-acid and salts of hmg-co-a reductase inhibitors - Google Patents

Dihydroxy open-acid and salts of hmg-co-a reductase inhibitors Download PDF

Info

Publication number
CA2364253A1
CA2364253A1 CA002364253A CA2364253A CA2364253A1 CA 2364253 A1 CA2364253 A1 CA 2364253A1 CA 002364253 A CA002364253 A CA 002364253A CA 2364253 A CA2364253 A CA 2364253A CA 2364253 A1 CA2364253 A1 CA 2364253A1
Authority
CA
Canada
Prior art keywords
compound
dihydroxy open
open acid
simvastatin
release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002364253A
Other languages
English (en)
French (fr)
Inventor
Richard D. Tillyer
Paul J. Reider
Edward J. J. Grabowski
Feng Xu
Jose M. Vega
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2364253A1 publication Critical patent/CA2364253A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CA002364253A 1999-03-08 2000-02-02 Dihydroxy open-acid and salts of hmg-co-a reductase inhibitors Abandoned CA2364253A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12322799P 1999-03-08 1999-03-08
US60/123,227 1999-03-08
US26474499A 1999-03-09 1999-03-09
US09/264,744 1999-03-09
PCT/US2000/002626 WO2000053173A1 (en) 1999-03-08 2000-02-02 Dihydroxy open-acid and salts of hmg-co-a reductase inhibitors

Publications (1)

Publication Number Publication Date
CA2364253A1 true CA2364253A1 (en) 2000-09-14

Family

ID=26821357

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002364253A Abandoned CA2364253A1 (en) 1999-03-08 2000-02-02 Dihydroxy open-acid and salts of hmg-co-a reductase inhibitors

Country Status (9)

Country Link
EP (1) EP1161236A1 (es)
JP (2) JP2002538202A (es)
AR (1) AR022856A1 (es)
AU (1) AU2866400A (es)
CA (1) CA2364253A1 (es)
CO (1) CO5150193A1 (es)
PE (1) PE20001559A1 (es)
SV (1) SV2002000036A (es)
WO (1) WO2000053173A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001032161A2 (en) * 1999-11-04 2001-05-10 Andrx Corporation Use of a hmg-coa reductase inhibitor for treating amyloid beta precursor disorders
EP1324972A4 (en) * 2000-09-06 2004-06-30 Merck & Co Inc OPEN-CHAIN DIHYDROXY ACID SALT BY SIMVASTATIN
AU9422101A (en) * 2000-10-12 2002-04-22 Nissan Chemical Ind Ltd Preventives and remedies for complications of diabetes
US6777552B2 (en) 2001-08-16 2004-08-17 Teva Pharmaceutical Industries, Ltd. Processes for preparing calcium salt forms of statins
NZ529913A (en) * 2001-08-16 2005-03-24 Teva Pharma Processes for preparing calcium salt forms of statins
DE60313125T2 (de) * 2002-01-09 2007-12-20 Crucell Holland B.V. Verwendung von erythropoietin zur behandlung oder vorbeugung von herzversagen
TW200404544A (en) * 2002-06-17 2004-04-01 Kowa Co Controlled release pharmaceutical composition
AR040588A1 (es) 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
US8987322B2 (en) * 2003-11-04 2015-03-24 Circ Pharma Research And Development Limited Pharmaceutical formulations for carrier-mediated transport statins and uses thereof
WO2005046662A2 (en) * 2003-11-07 2005-05-26 Jj Pharma, Inc. Hdl-boosting combination therapy complexes
US10208351B2 (en) 2013-10-18 2019-02-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) RNY-derived small RNAs as biomarkers for atherosclerosis-related disorders
EP3624789A4 (en) 2017-05-15 2021-02-17 University of Cincinnati COMPOSITIONS AND METHODS OF TREATMENT OF DEFECTS IN AVASCULAR CARTILAGE TISSUE BY DIRECT ADMINISTRATION OF ONE OR MORE METABOLITES OF SIMVASTATIN
CN113134086B (zh) * 2020-01-20 2024-05-24 深圳市长卿医学研究院 一种降血脂的药物组合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225202A (en) * 1991-09-30 1993-07-06 E. R. Squibb & Sons, Inc. Enteric coated pharmaceutical compositions
HU217629B (hu) * 1991-12-12 2000-03-28 Novartis Ag. Eljárás fluvasztatint tartalmazó stabilizált gyógyszerkészítmények előállítására
AU725622B2 (en) * 1995-12-22 2000-10-19 Kowa Company, Ltd. Pharmaceutical composition stabilized with a basic agent
US5916595A (en) * 1997-12-12 1999-06-29 Andrx Pharmaceutials, Inc. HMG co-reductase inhibitor

Also Published As

Publication number Publication date
EP1161236A1 (en) 2001-12-12
SV2002000036A (es) 2002-02-05
JP2000256191A (ja) 2000-09-19
AU2866400A (en) 2000-09-28
CO5150193A1 (es) 2002-04-29
JP2002538202A (ja) 2002-11-12
WO2000053173A1 (en) 2000-09-14
PE20001559A1 (es) 2001-01-16
AR022856A1 (es) 2002-09-04

Similar Documents

Publication Publication Date Title
US6569461B1 (en) Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors
AU764048B2 (en) Crystalline hydrated dihydroxy open-acid simvastatin calcium salt
CA2364253A1 (en) Dihydroxy open-acid and salts of hmg-co-a reductase inhibitors
AU2002310409B2 (en) Orally administered dosage forms of GABA analog prodrugs having reduced toxicity
AU2010221167B2 (en) Oral dosage forms having a high loading of a gabapentin prodrug
JP4913796B2 (ja) γ−アミノ酪酸アナログの結晶形
HRP20030104A2 (en) Therapeutic combination
EP3666750A1 (en) Crystalline form of bempedoic acid
US20030176501A1 (en) Dihydroxy open-acid salt of simvastatin
CN101412690A (zh) 西洛多辛的药用酸加成盐及其制备方法和药物应用
EP1036563A1 (en) Delayed-release oral formulation of dihydroxy open acid simvastatin and salts and esters thereof
US20170001945A1 (en) Derivatives of polyhydroxy compounds
EP2024316B9 (en) Crystalline leukotriene b4
US20090306024A1 (en) Combination preparations of o-acetylsalicylic acid salts
US9969674B2 (en) MMF-derivatives of ethyleneglycols
US11795180B2 (en) Formulation of a pan-JAK inhibitor
ES2281594T3 (es) Procedimiento para la preparacion de adsorbatos de atorvastatina en polvo de flujo libre.
CN110183348A (zh) N-(3-硝基-4-烷氧基苯甲酰基)氨基酸类化合物、制备方法及其用途
JP2008162949A (ja) チアゾリジンジオン化合物を含有する糖尿病治療薬

Legal Events

Date Code Title Description
FZDE Dead